KRRO NASDAQ
Korro Bio, Inc.
1W: -12.2%
1M: -17.3%
3M: -18.2%
YTD: +30.4%
1Y: -34.4%
3Y: -64.1%
5Y: -97.4%
$10.50
-0.22 (-2.05%)
Weekly Expected Move ±8.6%
$9
$10
$11
$12
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$20.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$104.5M
52W Range5.204-55.89
Volume153,986
Avg Volume193,155
Beta2.11
Dividend—
Analyst Ratings
Company Info
CEORam Aiyar
Employees49
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websitekorrobio.com
One Kendall Square
Cambridge, MA 02139-1562
US
Cambridge, MA 02139-1562
US
781-315-4600
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Latest News
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Vincent Loic A | A-Award | 7,500 | — | 2026-07-15 |
| Dolan Oliver | A-Award | 5,500 | — | 2026-07-15 |
| Cerio Jeffrey | A-Award | 6,500 | — | 2026-07-15 |
| Chappell Todd | A-Award | 7,500 | — | 2026-07-15 |
| FORMELA JEAN FRANCOI | S-Sale | 817 | $13.96 | 2026-07-06 |